Showing 1 - 5 results of 5 for search 'Erika Rijavec', query time: 0.03s Refine Results
  1. 1
    Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

    Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors by Alice Indini, Erika Rijavec, Michele Ghidini, Alessio Cortellini, Francesco Grossi

    Published 2021-05-01
    Get full text
    Article
  2. 2
    The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score

    The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score by Michele Ghidini, Alice Indini, Erika Rijavec, Claudia Bareggi, Monica Cattaneo, Gianluca Tomasello, Barbara Galassi, Donatella Gambini, Francesco Grossi

    Published 2021-03-01
    Get full text
    Article
  3. 3
    Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario

    Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario by Francesco Trevisani, Federico Di Marco, Matteo Floris, Antonello Pani, Roberto Minnei, Mario Scartozzi, Alessio Cirillo, Alain Gelibter, Andrea Botticelli, Erika Rijavec, Monica Cattaneo, Ornella Garrone, Michele Ghidini

    Published 2022-04-01
    Get full text
    Article
  4. 4
    Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

    Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors by Carlo Genova, Roberta Tasso, Alessandra Rosa, Giovanni Rossi, Daniele Reverberi, Vincenzo Fontana, Silvia Marconi, Michela Croce, Maria Giovanna Dal Bello, Chiara Dellepiane, Marco Tagliamento, Maria Chiara Ciferri, Lodovica Zullo, Alessandro Fedeli, Angela Alama, Katia Cortese, Chiara Gentili, Eugenia Cella, Giorgia Anselmi, Marco Mora, Giulia Barletta, Erika Rijavec, Francesco Grossi, Paolo Pronzato, Simona Coco

    Published 2023-03-01
    Get full text
    Article
  5. 5
    First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 by Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo

    Published 2023-02-01
    Get full text
    Article

Search Tools: